Innovent Biologics, Inc. · HKEX:1801

Innovent Biologics — FY2018 Earnings Presentation

23 slides from Innovent Biologics's earnings presentation, March 2019

  1. Slide 1: 2018 Annual Results Presentation

    2018 Annual Results Presentation March 2019

  2. Slide 2: Disclaimer

    Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of Innovent Biologics (“Innovent” “we,” “us” or “our”), our bu

  3. Slide 3: Our Mission, Vision and Development Strategy

    Our Mission, Vision and Development Strategy Company  To develop and commercialize high quality Mission biopharmaceuticals that are affordable to ordinary people Company  To be the premier biopharmaceutical company Vision in China  Robust and high quality pipeline Company Strategy  Global standa

  4. Slide 4: Our History

    Our History 2011.8  Innovent was 2018 established  Listed on HKEX 2016  NDA for IBI-303, biosimilar to  Strategic  IBI-301,IBI-303, IBI-305 2013 adalimumab alliance with entered Phase III clinical  Tyvyt® granted marketing Adimab trials approval by the NMPA  Passed GMP audits on  Strategic p

  5. Slide 5: Major Accomplishments Since 2018

    Major Accomplishments Since 2018 First NDA Approval 1 Tyvyt® (sintilimab injection) was granted marketing approval by the NMPA on Dec 24, 2018 Three NDA Applications submitted to the NMPA 2 NDA application for sintilimab (Apr 2018), adalimumab biosimilar (Nov 2018) and bevacizumab biosimilar (Jan 20

  6. Slide 6: Robust Pipeline across Biologics and Small Molecules

    Robust Pipeline across Biologics and Small Molecules As of March 11, 2019 Status (China) IND Candidate/ Reference Drug Target(s) Therapeutic Area: Disease Indications Commercial Rights Pre-clinical (Filed) (Accepted) Phase1 Phase 2 Phase 3 NDA Launched Oncology: r/r Hodgkin’s lymphoma, 1L and 2L mel

  7. Slide 7: Sintilimab Injection - Tyvyt®

    Sintilimab Injection - Tyvyt® (信迪利单抗注射液– 达伯舒®) Tyvyt ® (sintilimab injection) has been granted marketing approval by the NMPA on December 24, 2018 Copyright© 2019 Innovent Biologics 6

  8. Slide 8: Clinical Highlight of Sintilimab (Tyvyt®)

    Clinical Highlight of Sintilimab (Tyvyt®) Cover Story of Sintilimab (Tyvyt®) by The Lancet Haematology Lancet Coverage  Significant unmet medical need for patients with classical Hodgkin’s lymphoma in China  Registration trial in 96 patients with relapsed or refractory classical Hodgkin’s lymphoma

  9. Slide 9: Clinical Development Programs for Sintilimab

    Clinical Development Programs for Sintilimab As of March 11, 2019 Status Phase 1 Mono-/Combo-Therapy (Other NDA NDA 1, 2, 3 Indication Components) 1a 1b Phase 2 Phase 3 Filed Approved China r/r Classical Hodgkin’s Lymphoma Mono 2L Squamous NSCLC Mono 1L Non-squamous NSCLC Combo (pemetrexed and plati

  10. Slide 10: Commercialization of Sintilimab (Tyvyt®)

    Commercialization of Sintilimab (Tyvyt®) Right Team and Strategy Experienced Team Strategy Led by former vice president and head of one of  Focus on the rapid delivery of sintilimab to Roche’s two oncology business units in China with  expertise in the fields of lung cancer, gastrointestinal marke

  11. Slide 11: Commercialization of Sintilimab (Tyvyt®)

    Commercialization of Sintilimab (Tyvyt®) Marketing Readiness Media Channel Launch Activities Research Fund Program  Press conference for sintilimab  Engage KOLs after the approval  To enhance HCP hands-on commercial launch from the NMPA (National Medical experiences Products Administration)  To

  12. Slide 12: Other Major Clinical Advancements

    Other Major Clinical Advancements Continuous Pipeline Enhancement throughout Stage of Development Pre-clinical IND Phase1 Phase 2 Phase 3 NDA Launched IBI-303 (Adalimumab) Filed NDA in Nov 2018 IBI-305 (Bevacizumab) Filed NDA in Jan 2019 China IBI-101 (OX40) First Patient Dosed in Feb 2019 IBI-188 (

  13. Slide 13: State-of-the-art Manufacturing Facilities Designed to, Built to and Operating at International Standards

    State-of-the-art Manufacturing Facilities Designed to, Built to and Operating at International Standards M1b Facility Total capacity in the future: 81KL 4 x 15,000 L Planned 3 x 1,000 L In Operation 6 x 3,000 L (cGMP validated) Ready in 2019 On 29 December 2018, our manufacturing facilities received

  14. Slide 14: Global Partners

    Global Partners Strategic Partnership with Renowned MNCs Our Other Global R&D Partners March 20th 2015 October 12th 2015 July 2013  Innovent out licensed PD-1 mAb  Innovent out licensed Ex- Therapeutic Ex-China to Lilly China right of additional 3 PD- antibody discovery 1 bispecific mAbs to Lilly

  15. Slide 15: Pipeline Expansion through Partnership

    Pipeline Expansion through Partnership Product Candidates Licensed from Incyte for China Market Dec 17th 2018  Strengthened portfolio by licensing in 3 potentially Best-in-Class innovative late clinical-stage candidates, including 2 potentially First-in-Class candidates, for China development and c

  16. Slide 16: Strong Support from Globally Renowned Investors

    Strong Support from Globally Renowned Investors Ten Cornerstone Investors with an Aggregate Amount of US$245 mm US$20 mm ~US$20 mm US$25 mm US$20 mm US$5 mm US$60 mm US$15 mm US$30 mm US$20 mm US$30 mm Copyright© 2019 Innovent Biologics 15

  17. Slide 17: Corporate Milestones

    Corporate Milestones Listed on HKEX with stock code: 01801.HK, raising HK$3.8 billion (US$485 mm) on Oct. 31, 2018 Largest pre-revenue IPO at the time Stock price increased over 100% since IPO¹ Superior pricing outcome with significant over-subscription Awarded by IFR2 Awarded by IFR2 as Asia as “As

  18. Slide 18: Management with a Proven Track Record of Success

    Management with a Proven Track Record of Success Visionary Founder, CEO and Chairman Supported by Experienced Management Team Founder, CEO & Chairman Dr. Michael Yu  22 years of industry experience Founder, CEO & Chairman — 1997 – 2001: Vice President, Calydon  Ph.D. in Genetics, Chinese Academy o

  19. Slide 19: Innovent: A Platform Company

    Innovent: A Platform Company Fully-integrated Platform with World-class Discovery, Development, Manufacturing and Commercialization Capabilities IBI-377 IBI-307 IBI-939 IBI-188 IBI-315 IBI-385 IBI-323 IBI-110 IBI-303 IBI-306 IBI-322 IBI-376 IBI-319 IBI-101 IBI-305 IBI-302 IBI-318 IBI-301 IBI-308 IBI

  20. Slide 20: Our Growth Strategies

    Our Growth Strategies Our Mission To develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people 01 02 03 04 Maximize the value of our Enhance research and fully-integrated platform Rapidly advance our Continue to enhance our development capabilities through a gl

  21. Slide 21: Innovent at a Glance

    Innovent at a Glance Expect 4 products launched Multiple biologics in late stage development 20 drug candidates: • Tyvyt® launched Experienced Global R&D platform • 2 NDA filed (IBI-303 & IBI-305) management team • 1 Phase III mAb (IBI-301) Higher capacity GMP manufacturing facility Global standard

  22. Slide 22: Near Term Catalysts

    Near Term Catalysts Next 12 months 1 Launch and commercialization of sintilimab 2 IBI-301 (Rituximab biosimilar) to file NDA to the NMPA in Q4 2019 3 Continuous clinical advancement of a number of drug candidates 4 The 6*3000L M1b facility will be ready for production Copyright© 2019 Innovent Biolog

  23. Slide 23: Thank you! Q&A

    Start with Integrity, Succeed through Action Thanks Thank you! Q&A？ Copyright© 2019 Innovent Biologics 22

Innovent Biologics — FY2018 Earnings Presentation on 6ix